Central venous Access device SeCurement And Dressing Effectiveness in the ICU: the CASCADE ICU Trial
Phase 3
Completed
- Conditions
- Central venous access device failure prior to completion of therapyPublic Health - Health service research
- Registration Number
- ACTRN12615000667516
- Lead Sponsor
- Associate Professor Marion Mitchell
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
1. Informed written consent
2. Non-tunnelled percutaneous CVAD to be inserted in ICU for clinical care for >24 hours
Exclusion Criteria
1. Peripherally inserted, tunnelled, dialysis, or pulmonary artery catheters;
2. Current bloodstream infection;
3. CVAD to be inserted through diseased, burned, scarred or hirsute skin;
4. Allergy to any study product;
5. Previous study enrolment in this admission
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Feasibility of a full efficacy trial, established by a composite analyses of: eligibility, recruitment, retention and attrition, protocol adherence, missing data, intervention acceptability and effect size estimates. The primary outcome for the full efficacy trial which requires and effect size estimate is all-cause CVAD failure. [Study completion];CVAD failure: all-cause CVAD failure (composite of infection, occlusion, dislodgement, thrombosis, haematoma or breakage). Device failure is the outcome of importance to patients, with poor securement and dressing taking various pathways to the same endpoint – CVAD removal with requirement for a new CVAD insertion[CVAD removal]
- Secondary Outcome Measures
Name Time Method